Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.48 |
| ▸ | JAK1 | P23458 | 8/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | TYK2 | P29597 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | LTK | P29376 | 2/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.48 |
| ▸ | CLK2 | P49760 | 2/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.48 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26610798 | 1.00 | JAK2 (0.48) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL24902122 | 0.92 | PTGS1 (0.42) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL24902172 | 0.89 | JAK2 (0.46) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL27200387 | 0.89 | JAK2 (0.46) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL24902027 | 0.88 | JAK2 (0.52) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL26611582 | 0.88 | JAK2 (0.52) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL24902120 | 0.88 | JAK2 (0.52) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL26610418 | 0.87 | JAK2 (0.45) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL27246134 | 0.85 | JAK2 (0.47) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL30295213 | 0.84 | JAK2 (0.59) | JAK2JAK1JAK3TYK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2025-05-06 | — | — | US | disclosed |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA(SHANGHAI)CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| EP-4357346-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Coval Biopharma (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023001045-A9 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023001045-A9 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023001045-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | JAK2 4/4885JAK1 1/4885JAK3 20/4885 |
| US-12290519-B2 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | JAK1, TNF, CYP4A11 | JAK2 4/4885JAK1 1/4885JAK3 20/4885 |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | JAK2 4/4885JAK1 1/4885JAK3 20/4885 |
| US-20240197741-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TNF, CYP4A11, JAK1 | JAK2 4/4885JAK1 3/4885JAK3 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.